By Fineline Cube China’s National Medical Products Administration (NMPA), in coordination with the Ministry of Public Security and the Office of the National Narcotics Control Commission, has issued a joint regulatory notice imposing stringent new controls on oral single-ingredient pregabalin preparations and guaifenesin-containing cough syrups (defined as formulations containing only dextromethorphan and guaifenesin or guaifenesin glyceryl ether). The move reflects escalating concerns over non-medical use and diversion of these substances.
Key Regulatory Measures
| Requirement | Scope |
|---|---|
| API Quota Cap | Annual dextromethorphan API allocation for guaifenesin-combo production capped at prior-year levels |
| Purchaser Verification | Mandatory validation of buyer credentials, procurement staff ID, and specimen seals/signatures |
| Sales Monitoring | Distributors must conduct dynamic monitoring and regular audits of sales patterns |
| Abnormal Purchase Review | Triggered if volumes exceed normal business scale; requires evaluation of buyer’s safe handling protocols |
| Transaction Rules | Cash transactions prohibited; all payments must be traceable |
| Online Sales Ban | All online retail—direct or disguised—is forbidden |
| Pharmacy Protocols | Dedicated counters, trained staff, and separate physical registers required at point of sale |
Registration Requirements for Retail Pharmacies
Each transaction must record:
- Drug name and specification
- Sales quantity
- Manufacturer and batch number
- Purchase date
- Purchaser’s full name and national ID number
This level of documentation mirrors controls applied to Schedule II psychotropic substances under Chinese law, signaling a de facto reclassification in practice—even if not formally relabeled.
Background & Rationale
While pregabalin is approved for neuropathic pain and epilepsy, and dextromethorphan-guaifenesin combinations are common OTC cough remedies, both have been increasingly abused for psychoactive effects—particularly among adolescents. Recent seizures and social media-fueled misuse trends prompted inter-agency intervention.
The policy aligns with China’s broader “zero tolerance” narcotics strategy, which has previously led to strict controls on tramadol, codeine, and ephedrine-containing products.
Industry Impact
- Manufacturers: Face reduced API quotas and heightened compliance burdens; innovation in abuse-deterrent formulations may accelerate
- Distributors: Must implement real-time analytics to flag anomalous orders
- Retailers: Increased operational costs due to dedicated staffing and manual logging
- Market Contraction: Legal sales volume expected to decline 20–30% in 2026–2027 as access tightens
Multinational pharma firms with OTC portfolios in China—including GSK, Pfizer, and Sanofi—are assessing supply chain adjustments. Domestic players like Jiangsu Hengrui and Harbin Pharmaceutical may pivot to alternative cough/cold formulations.
Forward‑Looking Statements
This brief summarizes regulatory actions by Chinese authorities. Compliance timelines, enforcement rigor, and market responses remain subject to local implementation and monitoring.-Fineline Info & Tech